Eli Lilly and Boehringer Ingelheim Cancel Investments
A clear signal to Berlin: the pharmaceutical companies Eli Lilly and Boehringer Ingelheim are canceling planned investments in Germany.
Lilly
Lilly Deepens Lebanon Campus Investment with $4.5 Billion Commitment
Eli Lilly adds $4.5 billion to its Indiana manufacturing programme, funding a new genetic medicine facility and expanded API capacity at Lebanon, taking its total US investment since 2020 past $50 billion.
Lilly to Build $6.5 Billion US Pharmaceutical Plant
Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Houston, Texas.
“Access to Talent is a Crucial Factor”
In an interview with CHEManager, Edgardo Hernandez, President of Lilly Manufacturing, explains the strategy behind the ambitious investment project.
